Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of QLS-101 in SWS-Related Glaucoma
NCT04947124Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foslevcromakalim. Started Oct 2021; status: completed.
02
Drugs
foslevcromakalim
Beyond the preview
Go deeper on NCT04947124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947124.